ClinicalTrials.gg

Osteoporosis, Postmenopausal clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 334 studies for Osteoporosis, Postmenopausal across more than 10 countries. 28 are recruiting or about to start. 308 of them are mainly about Osteoporosis, Postmenopausal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
247
Status unknown
32
Recruiting
19
Active, not recruiting
12
Not yet recruiting
8
Terminated
7

Phase

Phase 3
74
Phase 4
73
Phase 2
34
Phase 1
24
Early Phase 1
1

Where

United States
106
Poland
36
Canada
26
Spain
26
China
25
Denmark
24

Who develops what

Add Osteoporosis, Postmenopausal to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 0 programs from 0 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DenosumabRecent, repeated
Evidence
  • NCT05419427 · lambda therapeutic research ltd · Phase 3 · live · comparator · “Denosumab-Ref” · registered Jun 2022
  • NCT05395091 · Alvotech Swiss AG · Phase 3 · comparator · “Denosumab” · registered May 2022
  • NCT05405725 · Enzene Biosciences Ltd. · Phase 3 · comparator · “Prolia” · registered May 2022
  • NCT05278338 · CSPC Pharmaceutical Group Limited · Phase 2 · comparator · “Denosumab” · registered Mar 2022
  • NCT05087030 · Gedeon Richter Plc. · Phase 3 · comparator · “Prolia®” · registered Oct 2021
Amgen70% of its industry studiesUS: Amgen (FDA 2010) + 9 othersEU: Amgen (EMA 2010) + 29 others44 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 0 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Osteoporosis, Postmenopausal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SERMs 12 · Statins 3

Coming up

15studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger. 1 (5%) take children under 18. 17 (89%) are for women only and 0 (0%) for men only; 7 (37%) take healthy volunteers.

Recruiting studies that take each age, of 19
AgeWomenMen
101 (5%)0 (0%)
184 (21%)1 (5%)
304 (21%)1 (5%)
406 (32%)2 (11%)
5018 (95%)2 (11%)
6518 (95%)2 (11%)
7513 (68%)1 (5%)
8512 (63%)1 (5%)

Across all 334 studies, recruiting or not: 24% stop at 75 or younger and 9% at 65; 12% take children; 93% are for women only and 1% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Osteoporosis, Postmenopausal studies take

Of 30 phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 324 mo20–44 · 30 studies24 mo19–43 · 29 studies—
Phase 434 mo22–66 · 27 studies——
Interventional, no phase17 mo9–34 · 50 studies—16 mo9–34 · 47 studies
Observational34 mo28–65 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 334. Browse all 334 → or search them.